Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2023-04-25 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于北京神州细胞生物技术集团股份公司2022年度募集资金存放与使用情况的专项核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项核查报告" (special inspection report) regarding the 2022 annual fundraising funds deposit and usage situation of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It is issued by CITIC Securities as the sponsor and continuous supervision institution. The document details the amounts raised in IPO and private placements, the usage and balance of the raised funds, compliance with regulatory requirements, and includes audit opinions from PwC. The document focuses exclusively on the management, deposit, and use of fundraising proceeds for the year 2022, with detailed financial figures and tables. It is not a full annual report (10-K), nor an earnings release or management discussion. It is a specialized audit/inspection report on fundraising funds usage, which fits the category of Audit Report / Information (AR). The document length is substantial and contains detailed financial data and audit opinions, not merely an announcement or certification. Therefore, the correct classification is AR with high confidence. FY 2022
2023-04-25 Chinese
神州细胞独立董事关于第二届董事会第五次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion report from the independent directors of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding various proposals discussed at the company's second board of directors' fifth meeting. It covers opinions on the 2022 fundraising usage report, internal control evaluation report, profit distribution plan, remuneration plans for directors and senior management, appointment of the audit firm for 2023, expected related party transactions, credit facilities and guarantees, appointment of the financial director, donation plans, and changes to IPO fundraising projects. The document references compliance with listing rules and company articles but does not contain actual financial statements or detailed financial data. It is a formal opinion document related to board meeting matters rather than a full annual report, audit report, or financial statement. The length is under 5,000 characters and it is a formal opinion on board meeting agenda items, which aligns with Board/Management Information filings (MANG).
2023-04-25 Chinese
神州细胞2022年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2022 年度内部控制评价报告' which translates to '2022 Annual Internal Control Evaluation Report'. It is a detailed report on the company's internal control effectiveness as of December 31, 2022. The content includes evaluation conclusions on financial and non-financial internal controls, defect recognition standards, scope of evaluation, and rectification status. It is a comprehensive internal control report rather than a brief announcement or certification. The document length is 4017 characters, which is relatively short but contains substantive evaluation content, not just a notice or certification. The document does not fit the categories of Annual Report (10-K), Interim Report (IR), or Audit Report (AR) exactly, but it is a standalone report on internal control evaluation, which aligns best with Audit Report / Information (AR) as it relates to internal control audit and evaluation results. Therefore, the most appropriate classification is AR with high confidence. FY 2022
2023-04-25 Chinese
神州细胞独立董事关于公司2022年度对外担保情况的专项说明
Audit Report / Information Classification · 95% confidence The document is titled as a special statement by independent directors regarding the company's external guarantees for the year 2022. It references regulatory rules related to listed companies, external guarantees, and the company's articles of association. The content includes specific financial figures about guarantees provided to subsidiaries and confirms compliance with legal and procedural requirements. The document is a standalone statement focusing on external guarantees and independent directors' opinions, not a full audit report or annual report. It is not a brief announcement or a certification letter but a special report on a specific topic. This fits the category of Audit Report / Information (AR), which includes standalone audit-related reports and applied accounting principles or regulatory compliance statements excluding full annual reports. FY 2022
2023-04-25 Chinese
中信证券股份有限公司关于北京神州细胞生物技术集团股份公司首次公开发行股票部分募投项目子项目变更及金额调整、新增募投项目及节余募集资金永久补充流动资金的专项核查报告
Audit Report / Information Classification · 95% confidence The document is a detailed special inspection report by CITIC Securities regarding changes and adjustments to the use of funds raised from the initial public offering (IPO) of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It discusses the reallocation of IPO proceeds among various clinical research projects, the addition of new projects, and the permanent supplementation of working capital. The document includes financial figures, project descriptions, regulatory references, and opinions from independent directors, the supervisory board, and the sponsor. It is a standalone audit or verification report related to the use of IPO proceeds and compliance with regulatory requirements, rather than a full annual or interim financial report. It is not a simple announcement or certification but a substantive report on the use of funds and project changes. Therefore, it fits best under the category of Audit Report / Information (AR). FY 2022
2023-04-25 Chinese
神州细胞2022年度董事会审计委员会履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2022年度董事会审计委员会履职情况报告" which translates to "2022 Annual Board Audit Committee Performance Report." It details the audit committee's activities, including supervision of external auditors, internal audit work, review of financial reports, internal control evaluation, and coordination with management and auditors. The document references the 2022 fiscal year and includes detailed descriptions of audit committee meetings and their oversight functions. It is not the full annual report or financial statements but a specific report on the audit committee's duties and findings for the year. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and related information excluding full annual reports. The document length is 4634 characters, which is sufficient to contain substantive content rather than a mere announcement. Therefore, the appropriate classification is AR with high confidence. FY 2022
2023-04-25 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.